$0.01
(1.43%)
Add to watchlist
Create an alert
Stocks and Shares ISAMatinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.
Company Information
About this company
Key people
Jerome D. Jabbour
Chairman of the Board, President, Chief Executive Officer, Director
Keith A. Kucinski
Chief Financial Officer
Evelyn D'An
Independent Director
Keith E. Murphy
Independent Director
Edward Neugeboren
Independent Director
Robin L. Smith
Independent Director
Click to see more
Key facts
- Shares in issue6.41m
- EPICMTNB
- ISINUS5768103039
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$4.55m
- Employees3
- ExchangeNyse American LLC
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.